GANX — Gain Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1819411 ·
Last close
$2.00
Market Cap
$87.29M
52W High
$2.37
52W Low
$1.56
ADV30
543,835
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,353,545 | -5,608,732 | 18,738,464 | 16,539,222 | 4,731,487 |
| Dec 2025 | 0 | — | -4,466,023 | -4,537,581 | 22,818,975 | 20,837,628 | 4,254,227 |
| Sep 2025 | 0 | — | -4,785,777 | -5,284,373 | 10,971,680 | 8,807,353 | 5,062,250 |
| Jun 2025 | 0 | — | -5,089,526 | -5,809,087 | 9,833,980 | 6,694,136 | 6,137,930 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-19,371,432
Investing CF
$0
Financing CF
$26,455,009
CapEx
$-945
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.63
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-106,964,739
Inventory
—
Receivables
$994,609
ST Investments
$0
EBIT TTM
$-19,694,871
Pretax Income TTM
$-20,296,098
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -18,710,702 | -20,161,099 | 22,818,975 | 4,254,227 | — | -18,465,432 |
| Dec 2024 | 0 | -20,350,592 | -20,411,191 | 12,123,884 | 4,784,310 | — | -18,873,827 |
| Dec 2023 | 55,180 | -22,253,133 | -22,267,520 | 18,609,331 | 6,031,107 | — | -18,865,873 |
| Dec 2022 | 140,108 | -17,777,045 | -17,590,738 | 24,099,387 | 5,219,873 | — | -14,692,139 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.54
Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $1.00 · spot: $2.00 · call volume: 250 · put volume: 51
Expected Move to 2026-09-18:
±$0.30
(14.75%) —
implied range
$1.71 –
$2.29
· ATM straddle on $2.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DWTX | Dogwood Therapeutics, Inc. | $87.02M | $2.56 | — |
| RVRC | Revium Rx. | $86.84M | $1.43 | — |
| LFVN | Lifevantage Corp | $86.29M | $6.84 | — |
| PLYX | Polaryx Therapeutics, Inc. | $88.53M | $1.87 | — |
| GOSS | Gossamer Bio, Inc. | $85.55M | $0.17 | — |
News headlines (Yahoo Finance, 1h cache)
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
2026-08-25 11:00 · Yahoo
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
2026-07-16 11:00 · Yahoo
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease
2026-06-29 20:05 · Yahoo
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
2026-06-10 11:00 · Yahoo
Gain Therapeutics expands ‘compelling’ evidence base for Parkinson’s candidate
2026-05-27 04:34 · Yahoo
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced
2026-05-22 00:58 · Yahoo
Gain Therapeutics (GANX) Shares Edge Higher After Narrower-Than-Expected Q1 Loss
2026-05-11 13:51 · Yahoo
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
2026-05-11 11:00 · Yahoo
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026
2026-04-24 12:30 · Yahoo
Why Is GANX Stock Rallying 22% After Hours?
2026-06-29 21:34 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.